



Aspira Pathlab & Diagnostics Limited

Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086

Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086

CIN: L85100MH1973PLC289209

Date: August 12, 2026

To,

Listing Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

Security Code: 540788

Security ID: ASPIRA

Sub: Outcome of Board Meeting held on Wednesday, August 12, 2026

Dear Sir/Madam,

In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. on Wednesday, August 12, 2026 inter alia, has considered, approved and taken on record the following matter(s):

1. Un-Audited Standalone Financial Results along with Limited Review Report for the first quarter ended June 30, 2026 ("the financial results") duly reviewed and approved by the Audit Committee and Board of Directors as per regulation 33 of the Listing Regulations is attached herewith.
2. The Board approved the Appointment of M/s. Harsh Kholiya & Co, Practicing Chartered Accountant (Firm Registration Number: 159312W), as an Internal Auditor of the Company for quarter 2, 3, and 4 for the Financial Year 2026-27.
3. The Board approved the appointment of Mr. Vaibhav Odhekar (DIN: 05135001) as Additional Executive Director with immediate effect, appointment subject to approval of the shareholders
4. The Board approved the Regularize of Mr. Vaibhav Odhekar DIN: 05135001 –As Executive Director subject to approval of the shareholders
5. The Board approved re-designation of Executive Director Mr. Nikunj Velji Mange (DIN: 08489442) as "Managing Director" of the company, subject to approval of shareholders in ensuing Annual General Meeting, with effect from 12.08.2026.
6. The Board of Directors considered the proposal for fund raising and, after due deliberation, decided not to take up the said agenda at the present meeting. Accordingly, no decision was taken by the Board in this regard.

Additional details pursuant to regulation 30 of the SEBI(LODR) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclose herewith in Annexure-A.

Pursuant to BSE Circular with ref. no. LIST/COMP/14/2018- 19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/ CML/2018/24, both dated 20th June 2018, we confirm that



Aspira Pathlab & Diagnostics Limited

Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086

Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086

CIN: L85100MH1973PLC289209

above Mr. Vaibhav Odhekar and Mr. Nikunj Velji Mange are not debarred from holding the office of Director by virtue of order of SEBI or any other such authority.

Kindly note that Board Meeting commenced at 01.00 P.M (IST) and concluded at 04.00 P.M.(IST)

The above information is being made available on the website of the Company

www.aspiradiagnostics.com.

We request you to kindly take the same on your record.

Thanking you.

Yours Faithfully,

For and on behalf of Board of Directors

Aspira Pathlab & Diagnostics Limited

Neetu Maurya

Company Secretary & Compliance Officer

A70372

Annexure-A

Details under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. no.	Particulars	Mr. Nikunj Velji Mange (DIN: 08489442)	Internal Auditor	Mr. VAIBHAV ODHEKAR (DIN: 05135001) As Additional Executive Director and Regularize subject to approval of shareholders in ensuing Annual General Meeting
1.	Reason for change viz. Appointment	Re-Design of Mr. Nikunj Velji Mange as a Managing Director of the company from August 12, 2026.	Appointment of M/s. Harsh Kholiya & Co, Practicing Chartered Accountant (Firm Registration Number: 159312W) as Internal Auditor of the Company.	Appointment of Mr. Vaibhav Odhekar as Additional Executive Director of the company from August 12, 2026
2.	Date of Appointment & term of appointment	The Board of Directors at its meeting held on August 12, 2026 approved the Re-Design of Mr. Nikunj Velji Mange as a Managing Director of the company from August 12, 2026.	The Board of Directors at its meeting held on August 12, 2026 approved the appointment M/s. Vishal J Bhanushali & Associates, as Internal Auditor of the Company for conducting Internal audit for quarter 2, 3, and 4 for the Financial Year 2026-27.	The Board of Directors at its meeting held on August 12, 2026 approved the appointment Mr. Vaibhav Odhekar as Additional Executive Director effective from August 12, 2026 and regularize subject to approval of Shareholder.
3.	Brief Profile	Mr. Nikunj Velji Mange has done Bachelor of Engineering in Computer Science, University of Mumbai, India. He is Master's student from The University of Texas at Arlington and over 12+ years of experience in the Software industry i.e. Experience in Analysis, Design, Development, and Implementation of various stand-alone, Intranets, Client-Server and Web Based Software applications using Microsoft Technologies including primary skills ASP.NET 3.5/4.5, Ajax, C#.NET, Java Script, Webservices, HTML, XML, Database queries, Stored Procedures, Views, Functions, SQL server	M/S. Harsh Kholiya & Co, Practicing Chartered Accountant: Mr. Harsh Arvindbhai Kholiya, is the professional experience in Audit, Accounting, Taxation, GST, Financial Reporting and Statutory Compliance, with practical exposure to independently handling audit and compliance assignments for companies, firms and other clients. Experienced in independent company audits, finalisation and review of books of accounts, tax audits, GST and Income-tax compliances, statutory filings and accounting reviews. Brings a control-oriented approach to identifying financial, compliance and process-level gaps and recommending practical corrective measures.	Mr. Vaibhav Odhekar is a seasoned entrepreneur and business executive with over 20 years of experience in technology-led platform businesses across India, Southeast Asia and the Middle East. He is the Co-founder of POKKT, one of APAC's leading mobile gaming monetization platforms, which was later merged with AnyMind Group, Japan, culminating in a Tokyo Stock Exchange listing. He has extensive experience in strategic growth, fundraising, cross-border operations, governance, mergers & acquisitions and scaling high-growth organizations. Mr. Vaibhav Odhekar has also served in leadership positions at AnyMind Group and Zapak Digital Entertainment Group and is

Aspira Pathlab & Diagnostics Limited

Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086

Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086

CIN: L85100MH1973PLC289209

		tuning, and Triggers Using SQL2012. He also has Comprehensive knowledge in the algorithm, data structures, Object-Oriented Analysis and Design, MVCarchitecture. He has worked for USA based company target base. Target base is a marketing firm that provides 360 services. He has also worked for Honda Project as technical head..		actively involved as an angel investor and advisor to emerging technology and consumer-focused businesses. He holds an MBA from Indian Institute of Management (IIM), Lucknow and a Bachelor of Engineering degree from Bhilai Institute of Technology, Durg.
4.	Disclosure of relationships between directors (in case of appointment of a director).	He is not related to any of the Directors/Key Managerial Personnel of the Company	Not Applicable	He is not related to any of the Directors/Key Managerial Personnel of the Company
5.	Terms of Appointment	5 years	9 Months	Not Applicable



Aspira Pathlab & Diagnostics Limited

Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086

Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086

CIN: L85100MH1973PLC289209

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE BOARD OF DIRECTORS OF ASPIRA PATHLAB & DIAGNOSTICS LIMITED ("THE COMPANY") IN ITS MEETING HELD ON WEDNESDAY , AUGUST 12, 2026 COMMENCED AT 01.00 P.M (IST) AT THROUGH VIDEO CONFERENCING AT UNIT 6 & 7, GROUND FLOOR, BHAVESHWAR ARCADE PREMISES CO-OP. SOCIETY LTD, NITYANAND NAGAR, GHATKOPAR WEST, MUMBAI, MAHARASHTRA 400086.

AUTHORISATION FOR SIGNING OF THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2026

"RESOLVED THAT pursuant to regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the unaudited standalone results for the first quarter ended June 30, 2026 be and is hereby approved.

RESOLVED FURTHER THAT pursuant to regulation 33(2)(b) of the SEBI (LODR) Regulations, 2015, Mr. Nikunj Mange, Executive Director (DIN: 08489442) of the Company be and is hereby authorised on behalf of the Board members to sign the aforesaid unaudited standalone financial results for the first quarter ended June 30, 2026".

For and on behalf of

Aspira Pathlab & Diagnostics Limited

Neetu Maurya

Company Secretary & Compliance Officer

A70372



Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

Manoj Jain

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

Limited Review Report on unaudited standalone financial results of Aspira Pathlab and Diagnostics Limited for the quarter ended 30TH June, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**To the Board of Directors of
Aspira Pathlab & Diagnostics Limited**

We have reviewed the accompanying statement of **Unaudited Standalone Financial Results of Aspira Pathlab & Diagnostics Limited** (hereinafter referred to as "the Company") for the quarter ended 30th June, 2026 (the Statement'), being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").


This Statement, which is the responsibility of the company's management and approved by the company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of the company's personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the accounting principles laid down in Ind AS 34 prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.





For **SARDA SONI ASSOCIATES LLP**
Chartered Accountants
Firm Reg. No. 117235W


(MANOJ KUMAR JAIN)
Partner

Membership No.- 120788
UDIN : 26120788NPHSKW9352

Place- Mumbai
Date- 12.08.2026

Aspira Pathlab & Diagnostics Limited (CIN L85100MH1973PLC289209) Reg. Office : Flat No. 2, R.D. Shah Bldg., Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086 Statement of Financial Results for the Quarter ended 30th June 2026 (Rs. in Lakhs)				
	Quarter ended			Year ended
Particulars	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
	(Unaudited) (Refer Note 3)	(Unaudited) (Refer Note 3)	(Unaudited) (Refer Note 3)	(Audited)
1. Income				
(a) Revenue from Operations				
Sales/Income from Operations	616.91	652.24	524.80	2,498.20
(b) Other Income	11.95	13.92	10.77	51.59
Total income	628.85	666.17	535.57	2,549.79
2. Expenses				
(a) Cost of Materials consumed	87.75	121.98	89.60	452.04
(b) Laboratory Testing Charges	36.25	37.75	27.42	133.56
(c) Employee benefits expense	249.39	228.97	189.01	877.68
(d) Finance Costs	9.19	9.97	9.40	38.94
(d) Depreciation and amortisation expense	40.91	39.54	36.52	153.84
(e) Other expenses	209.13	296.86	136.67	888.60
Total Expenses	632.62	735.07	488.63	2,544.67
3. Profit / (Loss) before exceptional items and tax (1-2)	(3.77)	(68.91)	46.94	5.13
4. Exceptional Items	-	-	-	-
5. Profit / (Loss) before tax (3+4)	(3.77)	(68.91)	46.94	5.13
6. Tax Expenses	-	-	-	-
7. Profit / (Loss) after tax (5-6)	(3.77)	(68.91)	46.94	5.13
8. Other Comprehensive income (net of tax)		6.12		6.12
9. Total Comprehensive income (7+8)	(3.77)	(62.79)	46.94	11.25
10. Paid up Equity share capital (Face value of Rs.10/- each)	1,029.30	1,029.30	1,029.30	1,029.30
11. Other equity				193.80
12. Earning per share				
(a) Basic	(0.04)	(0.67)	0.46	0.05
(b) Diluted	(0.04)	(0.67)	0.46	0.05
Note 1. The above financial results of the Company were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meetings held on 12.08.2026. The statutory auditors of the Company have expressed an unmodified opinion thereon. 2. The financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable. 3. The figures for the quarter ended 31 March 2026 are the balancing figures between audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December 2025, which was subjected to limited review. 4. The Board of Directors of the Company, which has been identified as being the Chief operating decision maker, evaluates the Company's performance allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore, there is no reportable segment of the Company in accordance with requirement of Ind AS 108 - Operating Segment, notified under the Companies (Indian Accounting Standard) Rules, 2015. 5. The previous period figures have been regrouped/reclassified wherever required to make them comparable with the figure of the current period.				
FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED  Nikunj Munge Executive Director DIN. 08489442 Place : Mumbai Date : 12.08.2026   For Sarda Soni Associates LLP Chartered Accountants  CA Manoj Kumar Jain Partner Membership No. : 120788				



Aspira Pathlab & Diagnostics Limited

Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Date: August 12, 2026

To,
Listing Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

Security Code: 540788

Security ID: ASPIRA

Sub: Integrated Filing (Financial) for the quarter ended 30 June 2026

Respected Sir/Madam, In terms of provisions of Regulation 10(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated 31 December 2024, and BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2 January 2025; the Integrated Filing (Financial) for the quarter ended 30 June 2026 is enclosed herewith.

We request you to kindly take this on record.

Thanking You,
Yours Faithfully,

For and on behalf of
Aspira Pathlab & Diagnostics Limited

Neetu Maurya
Company Secretary & Compliance Officer
A70372

Financial Result – Annexure A

A. Statement on deviation or variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc.: **Not Applicable**

B. Format for disclosing outstanding default on Loans and Debt Securities: **Not Applicable as we don't have any default on loans and debt securities outstanding as on June 30, 2026**

Sr. No.	Particulars	in ₹ crore
1.	Loans / revolving facilities like cash credit from banks / financial institutions	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
2.	Unlisted debt securities i.e. NCDs and NCRPS	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
3.	Total financial indebtedness of the listed entity including short term and long-term debt	0

C. Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter): **Applicable for this Quarter**

D. Statement on Impact of Audit Qualifications (for Audit Report with modified opinion) submitted along-with annual Audited Financial Results (Standalone) (applicable only for Annual Filing i.e., 4th quarter): **Applicable for this Quarter**